| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 81 | 2026 | 700 | 12.590 |
Why?
|
| Neoplastic Stem Cells | 51 | 2025 | 409 | 11.280 |
Why?
|
| Leukemia | 24 | 2025 | 247 | 5.110 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 20 | 2026 | 293 | 4.370 |
Why?
|
| Hematopoietic Stem Cells | 44 | 2026 | 435 | 3.690 |
Why?
|
| Sesquiterpenes | 25 | 2024 | 52 | 3.650 |
Why?
|
| Sulfonamides | 20 | 2026 | 596 | 3.510 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 25 | 2026 | 2001 | 2.410 |
Why?
|
| Antineoplastic Agents | 34 | 2025 | 2231 | 2.370 |
Why?
|
| Azacitidine | 15 | 2026 | 168 | 1.990 |
Why?
|
| Myelodysplastic Syndromes | 11 | 2026 | 170 | 1.600 |
Why?
|
| Drug Resistance, Neoplasm | 17 | 2025 | 889 | 1.560 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 8 | 2025 | 128 | 1.390 |
Why?
|
| Leukemia, Myeloid | 9 | 2011 | 49 | 1.390 |
Why?
|
| Oxidative Phosphorylation | 8 | 2024 | 212 | 1.390 |
Why?
|
| Drug Delivery Systems | 4 | 2019 | 381 | 1.290 |
Why?
|
| Cell Self Renewal | 3 | 2022 | 52 | 1.290 |
Why?
|
| Stem Cells | 11 | 2020 | 630 | 1.220 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 4 | 2019 | 241 | 1.140 |
Why?
|
| Gene Expression Regulation, Leukemic | 9 | 2016 | 56 | 1.120 |
Why?
|
| Mice | 74 | 2026 | 18491 | 1.030 |
Why?
|
| Protein Kinase Inhibitors | 8 | 2025 | 984 | 1.000 |
Why?
|
| Animals | 95 | 2026 | 38410 | 0.960 |
Why?
|
| Cell Transformation, Neoplastic | 7 | 2018 | 340 | 0.930 |
Why?
|
| Cell Line, Tumor | 32 | 2026 | 3565 | 0.910 |
Why?
|
| Humans | 168 | 2026 | 147293 | 0.900 |
Why?
|
| NF-kappa B | 15 | 2024 | 676 | 0.880 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2024 | 169 | 0.860 |
Why?
|
| Blast Crisis | 8 | 2025 | 34 | 0.840 |
Why?
|
| Apoptosis | 23 | 2024 | 2454 | 0.810 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 5 | 2013 | 347 | 0.810 |
Why?
|
| Mitochondria | 5 | 2026 | 1000 | 0.780 |
Why?
|
| Minor Histocompatibility Antigens | 2 | 2022 | 47 | 0.760 |
Why?
|
| Tumor Cells, Cultured | 18 | 2022 | 891 | 0.730 |
Why?
|
| Electron Transport Complex II | 2 | 2019 | 27 | 0.720 |
Why?
|
| Amino Acid Transport System ASC | 1 | 2022 | 12 | 0.710 |
Why?
|
| Cytarabine | 5 | 2019 | 66 | 0.690 |
Why?
|
| Signal Transduction | 18 | 2025 | 5272 | 0.690 |
Why?
|
| Antigens, CD34 | 12 | 2023 | 90 | 0.680 |
Why?
|
| Mice, Inbred NOD | 17 | 2020 | 616 | 0.680 |
Why?
|
| Neoplasm Proteins | 7 | 2016 | 445 | 0.670 |
Why?
|
| Fatty Acids | 3 | 2020 | 461 | 0.660 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2018 | 299 | 0.650 |
Why?
|
| Cell Survival | 19 | 2022 | 1111 | 0.640 |
Why?
|
| AMP-Activated Protein Kinases | 2 | 2020 | 192 | 0.630 |
Why?
|
| Mice, SCID | 16 | 2020 | 369 | 0.620 |
Why?
|
| Lipase | 1 | 2020 | 76 | 0.620 |
Why?
|
| STAT3 Transcription Factor | 1 | 2022 | 215 | 0.620 |
Why?
|
| Aldehyde Dehydrogenase | 3 | 2017 | 99 | 0.610 |
Why?
|
| Cell Proliferation | 17 | 2024 | 2529 | 0.600 |
Why?
|
| Flow Cytometry | 14 | 2020 | 1172 | 0.590 |
Why?
|
| Leukopoiesis | 1 | 2019 | 11 | 0.590 |
Why?
|
| NADPH Oxidase 2 | 1 | 2019 | 32 | 0.580 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2019 | 16 | 0.580 |
Why?
|
| Glutathione | 4 | 2019 | 370 | 0.570 |
Why?
|
| Succinate Dehydrogenase | 4 | 2026 | 65 | 0.550 |
Why?
|
| Calcium | 1 | 2024 | 1197 | 0.550 |
Why?
|
| Amino Acids | 2 | 2020 | 519 | 0.540 |
Why?
|
| Gene Expression Profiling | 7 | 2024 | 1794 | 0.540 |
Why?
|
| Cysteine | 1 | 2019 | 211 | 0.530 |
Why?
|
| Hematopoiesis | 11 | 2015 | 195 | 0.510 |
Why?
|
| Reactive Oxygen Species | 7 | 2020 | 616 | 0.500 |
Why?
|
| Interleukin-3 Receptor alpha Subunit | 4 | 2019 | 17 | 0.490 |
Why?
|
| Mitochondrial Proteins | 2 | 2018 | 264 | 0.490 |
Why?
|
| Mutation | 10 | 2026 | 4130 | 0.480 |
Why?
|
| Triterpenes | 2 | 2014 | 27 | 0.470 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 8 | 2022 | 51 | 0.460 |
Why?
|
| Energy Metabolism | 5 | 2021 | 936 | 0.460 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2016 | 103 | 0.450 |
Why?
|
| Cells, Cultured | 15 | 2019 | 4169 | 0.450 |
Why?
|
| Homeostasis | 2 | 2021 | 651 | 0.450 |
Why?
|
| Mice, Inbred C57BL | 23 | 2021 | 6041 | 0.450 |
Why?
|
| Liver | 7 | 2020 | 1916 | 0.440 |
Why?
|
| Sirolimus | 5 | 2016 | 283 | 0.440 |
Why?
|
| Membrane Proteins | 6 | 2024 | 1171 | 0.440 |
Why?
|
| Xenograft Model Antitumor Assays | 15 | 2020 | 939 | 0.440 |
Why?
|
| Oxidation-Reduction | 6 | 2019 | 1077 | 0.430 |
Why?
|
| Neoplasms | 7 | 2015 | 2946 | 0.420 |
Why?
|
| TOR Serine-Threonine Kinases | 4 | 2025 | 456 | 0.410 |
Why?
|
| Benzofurans | 1 | 2014 | 26 | 0.400 |
Why?
|
| Multiple Myeloma | 3 | 2024 | 310 | 0.400 |
Why?
|
| Thiadiazoles | 3 | 2011 | 25 | 0.400 |
Why?
|
| Phosphoproteins | 3 | 2020 | 337 | 0.400 |
Why?
|
| Interferon Regulatory Factors | 3 | 2024 | 45 | 0.400 |
Why?
|
| Dioxolanes | 1 | 2013 | 6 | 0.400 |
Why?
|
| Niacinamide | 3 | 2026 | 104 | 0.400 |
Why?
|
| Transduction, Genetic | 7 | 2006 | 133 | 0.390 |
Why?
|
| Fusion Proteins, bcr-abl | 4 | 2014 | 68 | 0.390 |
Why?
|
| Bone Marrow Cells | 12 | 2024 | 325 | 0.380 |
Why?
|
| Glucose | 1 | 2018 | 1051 | 0.380 |
Why?
|
| Enzyme Inhibitors | 5 | 2010 | 822 | 0.370 |
Why?
|
| Antibodies, Monoclonal | 8 | 2020 | 1514 | 0.360 |
Why?
|
| Oxidative Stress | 4 | 2014 | 1368 | 0.360 |
Why?
|
| Bone Marrow | 7 | 2024 | 310 | 0.350 |
Why?
|
| Cell Differentiation | 16 | 2022 | 2054 | 0.350 |
Why?
|
| Adaptation, Physiological | 1 | 2016 | 567 | 0.350 |
Why?
|
| Tumor Microenvironment | 5 | 2025 | 748 | 0.350 |
Why?
|
| Cell Death | 8 | 2012 | 383 | 0.350 |
Why?
|
| Oncogenes | 1 | 2012 | 118 | 0.350 |
Why?
|
| Adipose Tissue | 1 | 2016 | 646 | 0.350 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 2 | 2008 | 74 | 0.340 |
Why?
|
| Antigens, CD | 8 | 2010 | 562 | 0.340 |
Why?
|
| Adenoviridae | 3 | 2001 | 199 | 0.330 |
Why?
|
| Proto-Oncogene Proteins | 8 | 2021 | 627 | 0.330 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2025 | 1166 | 0.330 |
Why?
|
| Neoplasm, Residual | 4 | 2024 | 144 | 0.320 |
Why?
|
| Glycolysis | 2 | 2025 | 341 | 0.310 |
Why?
|
| Antineoplastic Agents, Phytogenic | 2 | 2015 | 178 | 0.310 |
Why?
|
| Gene Transfer Techniques | 4 | 2001 | 189 | 0.310 |
Why?
|
| Insulin Resistance | 1 | 2018 | 1253 | 0.300 |
Why?
|
| Leukemia, Experimental | 2 | 2006 | 27 | 0.300 |
Why?
|
| RNA Splicing Factors | 2 | 2020 | 66 | 0.300 |
Why?
|
| Oncogene Proteins, Fusion | 4 | 2013 | 212 | 0.290 |
Why?
|
| Models, Biological | 7 | 2011 | 1772 | 0.290 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 8 | 2022 | 703 | 0.290 |
Why?
|
| Proto-Oncogene Proteins c-jun | 1 | 2009 | 54 | 0.290 |
Why?
|
| Structure-Activity Relationship | 9 | 2021 | 567 | 0.280 |
Why?
|
| Lymphoid Progenitor Cells | 1 | 2008 | 11 | 0.280 |
Why?
|
| Transcriptome | 6 | 2024 | 1059 | 0.280 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2010 | 383 | 0.270 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2019 | 2030 | 0.270 |
Why?
|
| Hematologic Neoplasms | 3 | 2017 | 169 | 0.270 |
Why?
|
| Disease Models, Animal | 10 | 2020 | 4604 | 0.270 |
Why?
|
| Drug Screening Assays, Antitumor | 9 | 2021 | 194 | 0.270 |
Why?
|
| Immunophenotyping | 8 | 2016 | 325 | 0.270 |
Why?
|
| Neoplasm Transplantation | 6 | 2016 | 246 | 0.270 |
Why?
|
| Female | 44 | 2026 | 80076 | 0.270 |
Why?
|
| Indoles | 3 | 2017 | 510 | 0.260 |
Why?
|
| Membrane Potential, Mitochondrial | 2 | 2025 | 75 | 0.250 |
Why?
|
| Cell Lineage | 6 | 2012 | 381 | 0.250 |
Why?
|
| Genetic Vectors | 5 | 2001 | 335 | 0.250 |
Why?
|
| Stem Cell Transplantation | 2 | 2005 | 189 | 0.250 |
Why?
|
| Hematopoietic System | 1 | 2006 | 7 | 0.250 |
Why?
|
| Prognosis | 9 | 2025 | 4383 | 0.240 |
Why?
|
| Drug Design | 4 | 2016 | 177 | 0.240 |
Why?
|
| Gene Expression Regulation, Neoplastic | 7 | 2024 | 1457 | 0.230 |
Why?
|
| Tumor Suppressor Protein p53 | 6 | 2014 | 536 | 0.230 |
Why?
|
| Tanacetum parthenium | 1 | 2005 | 1 | 0.230 |
Why?
|
| Software | 2 | 2025 | 683 | 0.230 |
Why?
|
| Tumor Burden | 3 | 2016 | 327 | 0.230 |
Why?
|
| Interleukin-1 Receptor-Associated Kinases | 1 | 2025 | 41 | 0.230 |
Why?
|
| NAD | 1 | 2026 | 79 | 0.220 |
Why?
|
| Programming Languages | 1 | 2025 | 24 | 0.220 |
Why?
|
| Cell Cycle | 5 | 2021 | 600 | 0.220 |
Why?
|
| Myeloid Cells | 1 | 2006 | 150 | 0.220 |
Why?
|
| Mice, Transgenic | 5 | 2019 | 2197 | 0.220 |
Why?
|
| Single-Cell Analysis | 2 | 2025 | 367 | 0.220 |
Why?
|
| Taurine | 1 | 2025 | 41 | 0.220 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2026 | 256 | 0.210 |
Why?
|
| ras GTPase-Activating Proteins | 1 | 2024 | 16 | 0.210 |
Why?
|
| Ikaros Transcription Factor | 1 | 2024 | 23 | 0.210 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 7 | 2015 | 980 | 0.210 |
Why?
|
| Histiocytic Sarcoma | 1 | 2024 | 3 | 0.210 |
Why?
|
| Information Storage and Retrieval | 1 | 2025 | 123 | 0.210 |
Why?
|
| Thalidomide | 1 | 2024 | 43 | 0.210 |
Why?
|
| Molecular Targeted Therapy | 5 | 2019 | 444 | 0.200 |
Why?
|
| Hemangiosarcoma | 1 | 2024 | 27 | 0.200 |
Why?
|
| Carcinogenesis | 1 | 2025 | 230 | 0.190 |
Why?
|
| Male | 36 | 2026 | 73950 | 0.190 |
Why?
|
| Disease Progression | 6 | 2025 | 2890 | 0.190 |
Why?
|
| Acute Disease | 6 | 2005 | 1049 | 0.190 |
Why?
|
| Retroviridae | 6 | 2006 | 100 | 0.190 |
Why?
|
| Nuclear Proteins | 4 | 2024 | 745 | 0.190 |
Why?
|
| Drug Discovery | 3 | 2013 | 153 | 0.190 |
Why?
|
| Pyrroles | 2 | 2015 | 221 | 0.180 |
Why?
|
| Pyrimidines | 2 | 2017 | 532 | 0.180 |
Why?
|
| Spliceosomes | 2 | 2020 | 54 | 0.180 |
Why?
|
| Aged, 80 and over | 9 | 2025 | 8430 | 0.180 |
Why?
|
| Protein Biosynthesis | 2 | 2025 | 452 | 0.180 |
Why?
|
| Serine-Arginine Splicing Factors | 2 | 2019 | 27 | 0.180 |
Why?
|
| Osteoblasts | 4 | 2012 | 146 | 0.180 |
Why?
|
| Interleukin-1 | 1 | 2025 | 961 | 0.170 |
Why?
|
| Cytokines | 8 | 2026 | 2086 | 0.170 |
Why?
|
| Drug Synergism | 5 | 2020 | 355 | 0.170 |
Why?
|
| Transplantation, Heterologous | 3 | 2010 | 170 | 0.170 |
Why?
|
| Aged | 13 | 2025 | 26514 | 0.170 |
Why?
|
| Benzothiazoles | 3 | 2022 | 39 | 0.170 |
Why?
|
| c-Mer Tyrosine Kinase | 2 | 2018 | 39 | 0.170 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 2 | 2022 | 69 | 0.170 |
Why?
|
| Forkhead Transcription Factors | 2 | 2019 | 210 | 0.170 |
Why?
|
| Trans-Activators | 2 | 2021 | 398 | 0.160 |
Why?
|
| Leukocytes | 1 | 2002 | 301 | 0.160 |
Why?
|
| Receptors, Interleukin-3 | 1 | 2000 | 5 | 0.160 |
Why?
|
| Genes, Tumor Suppressor | 1 | 2001 | 86 | 0.160 |
Why?
|
| Nuclear Receptor Co-Repressor 2 | 1 | 2020 | 11 | 0.160 |
Why?
|
| Bone Marrow Diseases | 1 | 2020 | 20 | 0.160 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinases | 1 | 2001 | 165 | 0.160 |
Why?
|
| Biomarkers, Tumor | 5 | 2024 | 1339 | 0.160 |
Why?
|
| Mice, Knockout | 7 | 2016 | 3153 | 0.160 |
Why?
|
| Recurrence | 6 | 2025 | 1151 | 0.160 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2020 | 48 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2020 | 56 | 0.160 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2002 | 196 | 0.160 |
Why?
|
| Cell Separation | 5 | 2011 | 306 | 0.160 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2024 | 932 | 0.160 |
Why?
|
| Breast Neoplasms | 3 | 2015 | 2420 | 0.160 |
Why?
|
| Repressor Proteins | 2 | 2020 | 429 | 0.150 |
Why?
|
| Molecular Structure | 6 | 2018 | 488 | 0.150 |
Why?
|
| Membrane Glycoproteins | 6 | 2025 | 499 | 0.150 |
Why?
|
| Graft vs Host Disease | 1 | 2022 | 280 | 0.150 |
Why?
|
| Germ-Line Mutation | 1 | 2020 | 180 | 0.150 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 4 | 2015 | 231 | 0.150 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2015 | 196 | 0.150 |
Why?
|
| Cell-Derived Microparticles | 1 | 2020 | 73 | 0.150 |
Why?
|
| Cytochrome P-450 Enzyme System | 3 | 2016 | 163 | 0.140 |
Why?
|
| Splicing Factor U2AF | 1 | 2019 | 18 | 0.140 |
Why?
|
| Bone Marrow Transplantation | 3 | 2016 | 298 | 0.140 |
Why?
|
| Tricarboxylic Acids | 1 | 2018 | 11 | 0.140 |
Why?
|
| Inflammation | 3 | 2021 | 2920 | 0.140 |
Why?
|
| Blotting, Western | 5 | 2015 | 1186 | 0.140 |
Why?
|
| Histone Deacetylases | 1 | 2020 | 208 | 0.140 |
Why?
|
| Ketoglutaric Acids | 1 | 2018 | 22 | 0.140 |
Why?
|
| Infertility | 1 | 1999 | 62 | 0.140 |
Why?
|
| HEK293 Cells | 2 | 2019 | 745 | 0.140 |
Why?
|
| Glutamine | 1 | 2019 | 110 | 0.140 |
Why?
|
| Thrombocytopenia | 1 | 2020 | 207 | 0.140 |
Why?
|
| Gender Identity | 1 | 1999 | 133 | 0.140 |
Why?
|
| Genes | 1 | 1998 | 230 | 0.140 |
Why?
|
| Cytoprotection | 2 | 2016 | 56 | 0.140 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 3 | 2010 | 751 | 0.140 |
Why?
|
| Antibiotics, Antineoplastic | 2 | 2014 | 141 | 0.140 |
Why?
|
| Decision Support Systems, Clinical | 1 | 2022 | 278 | 0.140 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 2 | 2016 | 72 | 0.130 |
Why?
|
| Salvage Therapy | 1 | 2019 | 166 | 0.130 |
Why?
|
| Stress, Physiological | 1 | 2021 | 445 | 0.130 |
Why?
|
| RNA Interference | 3 | 2015 | 477 | 0.130 |
Why?
|
| Gene Expression | 5 | 2020 | 1481 | 0.130 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2008 | 76 | 0.130 |
Why?
|
| Arthritis, Experimental | 1 | 2019 | 136 | 0.130 |
Why?
|
| Phosphorylation | 5 | 2022 | 1721 | 0.130 |
Why?
|
| Biological Transport | 1 | 2018 | 425 | 0.130 |
Why?
|
| Succinates | 1 | 2017 | 25 | 0.130 |
Why?
|
| RNA, Messenger | 10 | 2011 | 2812 | 0.130 |
Why?
|
| Carboxylic Acids | 1 | 2017 | 31 | 0.130 |
Why?
|
| Recombinational DNA Repair | 1 | 2017 | 19 | 0.130 |
Why?
|
| Boronic Acids | 3 | 2013 | 37 | 0.130 |
Why?
|
| Drug Therapy, Combination | 2 | 2017 | 1046 | 0.130 |
Why?
|
| Diet, High-Fat | 1 | 2018 | 267 | 0.120 |
Why?
|
| Proteasome Inhibitors | 2 | 2020 | 42 | 0.120 |
Why?
|
| Triazoles | 1 | 2018 | 191 | 0.120 |
Why?
|
| Esters | 1 | 2017 | 71 | 0.120 |
Why?
|
| Phenotype | 4 | 2019 | 3216 | 0.120 |
Why?
|
| Clinical Trials as Topic | 2 | 2014 | 1072 | 0.120 |
Why?
|
| Phthalazines | 1 | 2017 | 63 | 0.120 |
Why?
|
| DNA Methylation | 2 | 2015 | 722 | 0.120 |
Why?
|
| Sulfhydryl Compounds | 2 | 2009 | 189 | 0.120 |
Why?
|
| NADP | 1 | 2016 | 52 | 0.120 |
Why?
|
| Phenylacetates | 1 | 2016 | 10 | 0.120 |
Why?
|
| Immunity, Innate | 2 | 2021 | 840 | 0.120 |
Why?
|
| Adenoviruses, Human | 1 | 1996 | 26 | 0.120 |
Why?
|
| Amides | 1 | 2017 | 101 | 0.120 |
Why?
|
| Adenosine Triphosphate | 1 | 2019 | 500 | 0.120 |
Why?
|
| CD36 Antigens | 1 | 2016 | 32 | 0.120 |
Why?
|
| Gonads | 1 | 2016 | 22 | 0.120 |
Why?
|
| Students, Medical | 1 | 2021 | 380 | 0.120 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2018 | 268 | 0.120 |
Why?
|
| Lipid Metabolism | 2 | 2018 | 538 | 0.120 |
Why?
|
| Deoxyglucose | 1 | 2016 | 51 | 0.120 |
Why?
|
| Pyrazines | 3 | 2013 | 94 | 0.120 |
Why?
|
| Lipolysis | 1 | 2016 | 44 | 0.120 |
Why?
|
| Genome, Human | 1 | 2018 | 426 | 0.120 |
Why?
|
| Glucosephosphate Dehydrogenase | 1 | 2016 | 70 | 0.120 |
Why?
|
| Neoplasms, Plasma Cell | 1 | 2015 | 5 | 0.120 |
Why?
|
| Treatment Outcome | 8 | 2026 | 11947 | 0.120 |
Why?
|
| Cell Division | 5 | 2004 | 758 | 0.120 |
Why?
|
| Neoplasms, Experimental | 2 | 2016 | 167 | 0.120 |
Why?
|
| Genomics | 2 | 2018 | 839 | 0.110 |
Why?
|
| Camptothecin | 1 | 2016 | 138 | 0.110 |
Why?
|
| Leukocytosis | 1 | 2015 | 32 | 0.110 |
Why?
|
| Oncogene Proteins | 1 | 2016 | 62 | 0.110 |
Why?
|
| Cysteine Proteinase Inhibitors | 2 | 2008 | 49 | 0.110 |
Why?
|
| Transplantation, Homologous | 4 | 2010 | 422 | 0.110 |
Why?
|
| Fetal Tissue Transplantation | 1 | 1995 | 33 | 0.110 |
Why?
|
| Up-Regulation | 2 | 2016 | 848 | 0.110 |
Why?
|
| DNA-Binding Proteins | 2 | 2013 | 1488 | 0.110 |
Why?
|
| Receptor-Interacting Protein Serine-Threonine Kinases | 1 | 2015 | 15 | 0.110 |
Why?
|
| Transcription Factors | 5 | 2022 | 1747 | 0.110 |
Why?
|
| Methyltransferases | 1 | 2016 | 75 | 0.110 |
Why?
|
| Cell Membrane | 3 | 2009 | 711 | 0.110 |
Why?
|
| Lactones | 3 | 2021 | 59 | 0.110 |
Why?
|
| Molecular Docking Simulation | 3 | 2021 | 119 | 0.110 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2019 | 356 | 0.110 |
Why?
|
| Clonal Evolution | 1 | 2015 | 47 | 0.110 |
Why?
|
| Oligomycins | 1 | 2014 | 7 | 0.110 |
Why?
|
| Doxycycline | 1 | 2015 | 62 | 0.110 |
Why?
|
| Histone Deacetylase Inhibitors | 2 | 2014 | 219 | 0.110 |
Why?
|
| Metabolome | 1 | 2018 | 391 | 0.110 |
Why?
|
| Autoimmune Diseases | 1 | 2019 | 471 | 0.110 |
Why?
|
| Mitochondrial Proton-Translocating ATPases | 1 | 2014 | 23 | 0.110 |
Why?
|
| Middle Aged | 14 | 2026 | 36821 | 0.110 |
Why?
|
| Piperazines | 1 | 2017 | 375 | 0.110 |
Why?
|
| Remission Induction | 4 | 2019 | 310 | 0.110 |
Why?
|
| Homeodomain Proteins | 5 | 2016 | 525 | 0.110 |
Why?
|
| Transcription Factor RelA | 2 | 2021 | 93 | 0.110 |
Why?
|
| Eukaryotic Initiation Factor-4E | 2 | 2005 | 32 | 0.100 |
Why?
|
| Glucuronosyltransferase | 1 | 2014 | 18 | 0.100 |
Why?
|
| Glucuronic Acid | 1 | 2014 | 30 | 0.100 |
Why?
|
| Peptide Hydrolases | 1 | 2015 | 105 | 0.100 |
Why?
|
| Phenylbutyrates | 1 | 2014 | 23 | 0.100 |
Why?
|
| I-kappa B Kinase | 1 | 2014 | 52 | 0.100 |
Why?
|
| Osteoclasts | 2 | 2011 | 57 | 0.100 |
Why?
|
| Dogs | 2 | 2024 | 518 | 0.100 |
Why?
|
| Necrosis | 1 | 2015 | 245 | 0.100 |
Why?
|
| Computational Biology | 1 | 2019 | 677 | 0.100 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2016 | 141 | 0.100 |
Why?
|
| Selenium | 1 | 2014 | 50 | 0.100 |
Why?
|
| Eicosanoids | 1 | 2014 | 58 | 0.100 |
Why?
|
| Multiprotein Complexes | 1 | 2015 | 172 | 0.100 |
Why?
|
| Piperidones | 1 | 2013 | 1 | 0.100 |
Why?
|
| Thiamine | 1 | 2014 | 19 | 0.100 |
Why?
|
| Glutamate-Cysteine Ligase | 1 | 2013 | 19 | 0.100 |
Why?
|
| Glutathione Peroxidase | 1 | 2013 | 41 | 0.100 |
Why?
|
| Adaptation, Psychological | 1 | 1999 | 736 | 0.100 |
Why?
|
| Hydrolases | 1 | 2014 | 41 | 0.100 |
Why?
|
| Genetic Heterogeneity | 1 | 2014 | 66 | 0.100 |
Why?
|
| Integrin beta3 | 1 | 2013 | 14 | 0.100 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2016 | 323 | 0.100 |
Why?
|
| Biomarkers | 2 | 2019 | 4351 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2017 | 518 | 0.100 |
Why?
|
| Hedgehog Proteins | 1 | 2014 | 201 | 0.090 |
Why?
|
| Tyrphostins | 1 | 2012 | 18 | 0.090 |
Why?
|
| Phenylurea Compounds | 3 | 2022 | 122 | 0.090 |
Why?
|
| Adult | 13 | 2026 | 41405 | 0.090 |
Why?
|
| Serpins | 1 | 2012 | 28 | 0.090 |
Why?
|
| Leupeptins | 2 | 2002 | 13 | 0.090 |
Why?
|
| Carrier Proteins | 2 | 2015 | 731 | 0.090 |
Why?
|
| Cytomegalovirus | 2 | 2004 | 172 | 0.090 |
Why?
|
| Mice, Inbred Strains | 3 | 2006 | 397 | 0.090 |
Why?
|
| Antifungal Agents | 1 | 2013 | 153 | 0.090 |
Why?
|
| Receptors, Immunologic | 3 | 2009 | 210 | 0.090 |
Why?
|
| Base Sequence | 7 | 2013 | 2175 | 0.090 |
Why?
|
| Survival Rate | 3 | 2019 | 2110 | 0.090 |
Why?
|
| Spleen | 3 | 2011 | 509 | 0.090 |
Why?
|
| Nitrogen Mustard Compounds | 1 | 2011 | 9 | 0.090 |
Why?
|
| Chemokine CCL3 | 1 | 2011 | 26 | 0.090 |
Why?
|
| Tumor Stem Cell Assay | 2 | 2015 | 34 | 0.080 |
Why?
|
| Cellular Microenvironment | 1 | 2012 | 94 | 0.080 |
Why?
|
| Pyridones | 1 | 2013 | 210 | 0.080 |
Why?
|
| Protein Domains | 2 | 2024 | 313 | 0.080 |
Why?
|
| ADP-ribosyl Cyclase 1 | 4 | 2009 | 43 | 0.080 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2014 | 590 | 0.080 |
Why?
|
| Prodrugs | 1 | 2011 | 54 | 0.080 |
Why?
|
| Seminal Vesicles | 1 | 2010 | 9 | 0.080 |
Why?
|
| Protease Inhibitors | 1 | 2011 | 104 | 0.080 |
Why?
|
| Gene Expression Regulation, Viral | 3 | 2002 | 93 | 0.080 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2004 | 669 | 0.080 |
Why?
|
| Stress, Psychological | 1 | 1999 | 1174 | 0.080 |
Why?
|
| Medication Adherence | 1 | 2015 | 540 | 0.080 |
Why?
|
| Chemokine CXCL12 | 1 | 2011 | 86 | 0.080 |
Why?
|
| Polymerase Chain Reaction | 6 | 2024 | 1046 | 0.080 |
Why?
|
| Sialic Acid Binding Ig-like Lectin 3 | 1 | 2010 | 10 | 0.080 |
Why?
|
| Genetic Markers | 3 | 1999 | 338 | 0.080 |
Why?
|
| Graft vs Tumor Effect | 1 | 2010 | 8 | 0.080 |
Why?
|
| Drug Evaluation, Preclinical | 2 | 2010 | 196 | 0.080 |
Why?
|
| Binding Sites | 3 | 2021 | 1319 | 0.080 |
Why?
|
| Immunosuppressive Agents | 1 | 2015 | 840 | 0.080 |
Why?
|
| Colony-Forming Units Assay | 4 | 2009 | 95 | 0.080 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2019 | 1183 | 0.080 |
Why?
|
| I-kappa B Proteins | 2 | 2017 | 75 | 0.080 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2010 | 66 | 0.080 |
Why?
|
| Ethanol | 1 | 2015 | 634 | 0.080 |
Why?
|
| Hyaluronan Receptors | 1 | 2010 | 105 | 0.080 |
Why?
|
| Retrospective Studies | 7 | 2024 | 17560 | 0.080 |
Why?
|
| Neutrophils | 1 | 2015 | 1135 | 0.080 |
Why?
|
| Receptors, Cell Surface | 3 | 2022 | 373 | 0.070 |
Why?
|
| K562 Cells | 2 | 2020 | 92 | 0.070 |
Why?
|
| Prostate | 1 | 2010 | 160 | 0.070 |
Why?
|
| Idarubicin | 2 | 2013 | 5 | 0.070 |
Why?
|
| Protein Kinase C | 2 | 2007 | 251 | 0.070 |
Why?
|
| Vidarabine | 1 | 2008 | 32 | 0.070 |
Why?
|
| Dinoprostone | 1 | 2009 | 180 | 0.070 |
Why?
|
| Radiation Oncology | 1 | 2009 | 83 | 0.070 |
Why?
|
| Kidney Transplantation | 1 | 2015 | 732 | 0.070 |
Why?
|
| Coculture Techniques | 2 | 2006 | 247 | 0.070 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2008 | 12 | 0.070 |
Why?
|
| RNA, Small Interfering | 3 | 2016 | 643 | 0.070 |
Why?
|
| Pentacyclic Triterpenes | 1 | 2008 | 12 | 0.070 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2008 | 12 | 0.070 |
Why?
|
| Rats | 5 | 2015 | 5613 | 0.070 |
Why?
|
| Machine Learning | 2 | 2025 | 596 | 0.070 |
Why?
|
| Lymphocytes | 3 | 1999 | 378 | 0.070 |
Why?
|
| RNA Splicing | 2 | 2020 | 285 | 0.070 |
Why?
|
| Terpenes | 1 | 2008 | 24 | 0.070 |
Why?
|
| Mice, Nude | 3 | 2015 | 680 | 0.070 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 5476 | 0.070 |
Why?
|
| Induction Chemotherapy | 2 | 2021 | 88 | 0.070 |
Why?
|
| Liver Transplantation | 1 | 1995 | 841 | 0.070 |
Why?
|
| Primary Cell Culture | 2 | 2020 | 173 | 0.070 |
Why?
|
| DNA Mismatch Repair | 1 | 2008 | 54 | 0.070 |
Why?
|
| Molecular Sequence Data | 6 | 2013 | 2886 | 0.070 |
Why?
|
| ADP-ribosyl Cyclase | 3 | 2004 | 6 | 0.060 |
Why?
|
| Genetic Therapy | 2 | 2000 | 317 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-kit | 2 | 2006 | 74 | 0.060 |
Why?
|
| Insulin | 1 | 2018 | 2526 | 0.060 |
Why?
|
| MicroRNAs | 1 | 2013 | 694 | 0.060 |
Why?
|
| T-Lymphocytes, Cytotoxic | 1 | 2008 | 179 | 0.060 |
Why?
|
| Biological Availability | 1 | 2007 | 146 | 0.060 |
Why?
|
| Bortezomib | 3 | 2013 | 54 | 0.060 |
Why?
|
| Aldehydes | 1 | 2008 | 140 | 0.060 |
Why?
|
| Mice, Inbred BALB C | 3 | 2016 | 1266 | 0.060 |
Why?
|
| Clone Cells | 3 | 2001 | 263 | 0.060 |
Why?
|
| Receptors, LDL | 1 | 2007 | 53 | 0.060 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2008 | 91 | 0.060 |
Why?
|
| Databases, Genetic | 1 | 2008 | 240 | 0.060 |
Why?
|
| Nicotinamide Phosphoribosyltransferase | 1 | 2026 | 26 | 0.060 |
Why?
|
| Phospholipases A | 1 | 2007 | 97 | 0.060 |
Why?
|
| Cell Line, Transformed | 1 | 2006 | 138 | 0.060 |
Why?
|
| RNA-Binding Proteins | 1 | 2010 | 451 | 0.060 |
Why?
|
| Receptors, Virus | 2 | 1997 | 95 | 0.060 |
Why?
|
| Young Adult | 5 | 2026 | 14437 | 0.060 |
Why?
|
| Proteasome Endopeptidase Complex | 2 | 2008 | 156 | 0.060 |
Why?
|
| Hodgkin Disease | 1 | 2008 | 173 | 0.060 |
Why?
|
| Interleukin-1 Receptor Accessory Protein | 1 | 2025 | 10 | 0.060 |
Why?
|
| Exome | 2 | 2018 | 233 | 0.060 |
Why?
|
| Receptors, Interleukin-1 Type I | 1 | 2025 | 25 | 0.060 |
Why?
|
| Biomedical Research | 2 | 2010 | 723 | 0.060 |
Why?
|
| Asparagine | 1 | 2025 | 35 | 0.060 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2008 | 421 | 0.060 |
Why?
|
| Plants, Medicinal | 1 | 2005 | 23 | 0.060 |
Why?
|
| Receptors, Notch | 1 | 2006 | 91 | 0.060 |
Why?
|
| Parathyroid Hormone | 1 | 2006 | 118 | 0.060 |
Why?
|
| Models, Genetic | 1 | 2008 | 536 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2014 | 432 | 0.060 |
Why?
|
| Myeloid Ecotropic Viral Integration Site 1 Protein | 2 | 2016 | 11 | 0.060 |
Why?
|
| Transcription, Genetic | 2 | 2009 | 1456 | 0.050 |
Why?
|
| Cardiolipins | 1 | 2025 | 82 | 0.050 |
Why?
|
| Gene Deletion | 2 | 2018 | 392 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2022 | 6099 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2008 | 430 | 0.050 |
Why?
|
| Graft Survival | 2 | 2009 | 534 | 0.050 |
Why?
|
| Calcium-Binding Proteins | 1 | 2006 | 222 | 0.050 |
Why?
|
| HSP90 Heat-Shock Proteins | 2 | 2015 | 47 | 0.050 |
Why?
|
| Drug Resistance | 1 | 2005 | 145 | 0.050 |
Why?
|
| Diphtheria Toxin | 1 | 2004 | 65 | 0.050 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2006 | 376 | 0.050 |
Why?
|
| Genome-Wide Association Study | 1 | 2011 | 1496 | 0.050 |
Why?
|
| Reference Values | 2 | 2007 | 800 | 0.050 |
Why?
|
| Arsenicals | 2 | 2017 | 28 | 0.050 |
Why?
|
| Oxides | 2 | 2017 | 47 | 0.050 |
Why?
|
| Protein Binding | 3 | 2020 | 2249 | 0.050 |
Why?
|
| NAD+ Nucleosidase | 2 | 2001 | 3 | 0.050 |
Why?
|
| Drug Evaluation | 1 | 2004 | 79 | 0.050 |
Why?
|
| Isocitrate Dehydrogenase | 1 | 2024 | 72 | 0.050 |
Why?
|
| GTP Phosphohydrolases | 1 | 2024 | 95 | 0.050 |
Why?
|
| Inflammation Mediators | 2 | 2020 | 507 | 0.050 |
Why?
|
| Membrane Transport Proteins | 1 | 2025 | 154 | 0.050 |
Why?
|
| Stereoisomerism | 2 | 2016 | 103 | 0.050 |
Why?
|
| Antigens, Differentiation | 2 | 2001 | 76 | 0.050 |
Why?
|
| Forecasting | 1 | 2005 | 391 | 0.050 |
Why?
|
| Translocation, Genetic | 1 | 2004 | 126 | 0.050 |
Why?
|
| Enzyme Activation | 3 | 2010 | 762 | 0.050 |
Why?
|
| Maximum Tolerated Dose | 2 | 2013 | 217 | 0.050 |
Why?
|
| Atherosclerosis | 1 | 2007 | 411 | 0.050 |
Why?
|
| Heat Shock Transcription Factors | 1 | 2022 | 22 | 0.050 |
Why?
|
| Multienzyme Complexes | 1 | 2002 | 65 | 0.050 |
Why?
|
| Organic Cation Transport Proteins | 1 | 2002 | 25 | 0.050 |
Why?
|
| Cysteine Endopeptidases | 1 | 2002 | 80 | 0.050 |
Why?
|
| Monocytes | 3 | 2018 | 539 | 0.050 |
Why?
|
| Lentivirus | 2 | 2019 | 62 | 0.050 |
Why?
|
| Everolimus | 1 | 2022 | 112 | 0.040 |
Why?
|
| Virus Latency | 1 | 2002 | 93 | 0.040 |
Why?
|
| Cytomegalovirus Infections | 1 | 2004 | 210 | 0.040 |
Why?
|
| Culture Media, Serum-Free | 1 | 2001 | 42 | 0.040 |
Why?
|
| Selective Estrogen Receptor Modulators | 1 | 2002 | 34 | 0.040 |
Why?
|
| Biopsy | 2 | 2015 | 1093 | 0.040 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2002 | 116 | 0.040 |
Why?
|
| Predictive Value of Tests | 2 | 2019 | 2133 | 0.040 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2001 | 17 | 0.040 |
Why?
|
| Aromatase Inhibitors | 1 | 2002 | 81 | 0.040 |
Why?
|
| Death-Associated Protein Kinases | 1 | 2001 | 10 | 0.040 |
Why?
|
| Enzyme Induction | 1 | 2001 | 88 | 0.040 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2012 | 337 | 0.040 |
Why?
|
| Models, Molecular | 2 | 2018 | 1606 | 0.040 |
Why?
|
| Allografts | 1 | 2021 | 152 | 0.040 |
Why?
|
| Megakaryocytes | 1 | 2020 | 34 | 0.040 |
Why?
|
| Hepatocytes | 1 | 2001 | 224 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2022 | 779 | 0.040 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2001 | 187 | 0.040 |
Why?
|
| DNA Primers | 2 | 2002 | 505 | 0.040 |
Why?
|
| Virus Diseases | 2 | 2000 | 218 | 0.040 |
Why?
|
| DNA | 4 | 2008 | 1444 | 0.040 |
Why?
|
| Mice, Inbred C3H | 2 | 1990 | 254 | 0.040 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2020 | 79 | 0.040 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 2 | 2010 | 153 | 0.040 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 1 | 1999 | 28 | 0.040 |
Why?
|
| Cell Line | 4 | 1999 | 2832 | 0.040 |
Why?
|
| Computer Simulation | 1 | 2024 | 1018 | 0.040 |
Why?
|
| Alleles | 1 | 2002 | 909 | 0.040 |
Why?
|
| Cell Hypoxia | 2 | 2011 | 249 | 0.040 |
Why?
|
| Radiation Chimera | 2 | 2008 | 28 | 0.040 |
Why?
|
| Thermodynamics | 1 | 2021 | 420 | 0.040 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2019 | 23 | 0.040 |
Why?
|
| Actins | 1 | 2001 | 428 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2018 | 1162 | 0.040 |
Why?
|
| RAW 264.7 Cells | 1 | 2019 | 51 | 0.040 |
Why?
|
| Protein Transport | 1 | 2020 | 442 | 0.040 |
Why?
|
| Infection Control | 1 | 2000 | 174 | 0.040 |
Why?
|
| Core Binding Factor Alpha 2 Subunit | 1 | 2018 | 32 | 0.040 |
Why?
|
| DNA (Cytosine-5-)-Methyltransferases | 1 | 2018 | 37 | 0.030 |
Why?
|
| Macrophages | 2 | 2018 | 1529 | 0.030 |
Why?
|
| Datasets as Topic | 1 | 2018 | 121 | 0.030 |
Why?
|
| Stromal Cells | 2 | 2012 | 123 | 0.030 |
Why?
|
| Retinal Dehydrogenase | 1 | 2017 | 29 | 0.030 |
Why?
|
| Proteomics | 1 | 2024 | 1203 | 0.030 |
Why?
|
| Cell Movement | 1 | 2001 | 966 | 0.030 |
Why?
|
| Phosphate Transport Proteins | 1 | 1996 | 2 | 0.030 |
Why?
|
| Interphase | 1 | 1996 | 38 | 0.030 |
Why?
|
| Adenovirus Infections, Human | 1 | 1996 | 15 | 0.030 |
Why?
|
| Bacillus megaterium | 1 | 2016 | 1 | 0.030 |
Why?
|
| Kinetics | 3 | 2011 | 1569 | 0.030 |
Why?
|
| NADPH-Ferrihemoprotein Reductase | 1 | 2016 | 10 | 0.030 |
Why?
|
| Heterografts | 1 | 2017 | 143 | 0.030 |
Why?
|
| Hydrazines | 1 | 2016 | 37 | 0.030 |
Why?
|
| Pyrimidinones | 1 | 2017 | 125 | 0.030 |
Why?
|
| HeLa Cells | 2 | 2014 | 633 | 0.030 |
Why?
|
| Genetic Testing | 1 | 2019 | 493 | 0.030 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 2016 | 23 | 0.030 |
Why?
|
| Acylation | 1 | 2016 | 30 | 0.030 |
Why?
|
| Symporters | 1 | 1996 | 48 | 0.030 |
Why?
|
| Cyclophosphamide | 1 | 2017 | 277 | 0.030 |
Why?
|
| Sequence Analysis, RNA | 1 | 2018 | 443 | 0.030 |
Why?
|
| Gliosarcoma | 1 | 2015 | 8 | 0.030 |
Why?
|
| Risk Assessment | 1 | 2025 | 3784 | 0.030 |
Why?
|
| Transfection | 1 | 1998 | 930 | 0.030 |
Why?
|
| COP9 Signalosome Complex | 1 | 2015 | 5 | 0.030 |
Why?
|
| Interleukin Receptor Common gamma Subunit | 1 | 2015 | 14 | 0.030 |
Why?
|
| Drug Therapy | 1 | 2016 | 84 | 0.030 |
Why?
|
| Dimerization | 1 | 2015 | 189 | 0.030 |
Why?
|
| Lipopolysaccharides | 1 | 2019 | 863 | 0.030 |
Why?
|
| Granulocyte Precursor Cells | 1 | 2015 | 9 | 0.030 |
Why?
|
| Dihydrolipoyllysine-Residue Acetyltransferase | 1 | 2014 | 6 | 0.030 |
Why?
|
| Ketone Oxidoreductases | 1 | 2014 | 7 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2015 | 168 | 0.030 |
Why?
|
| Amino Acid Sequence | 4 | 2005 | 2134 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2017 | 618 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 1 | 2017 | 855 | 0.030 |
Why?
|
| Imatinib Mesylate | 1 | 2014 | 77 | 0.030 |
Why?
|
| Ionomycin | 1 | 2014 | 22 | 0.030 |
Why?
|
| Lethal Dose 50 | 1 | 2014 | 17 | 0.030 |
Why?
|
| Splenomegaly | 1 | 2014 | 15 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2015 | 330 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2015 | 414 | 0.030 |
Why?
|
| Zinc Finger Protein GLI1 | 1 | 2014 | 25 | 0.030 |
Why?
|
| DNA Damage | 1 | 2017 | 440 | 0.030 |
Why?
|
| Cyclin D1 | 2 | 2005 | 64 | 0.030 |
Why?
|
| Amino Acids, Aromatic | 1 | 2014 | 6 | 0.030 |
Why?
|
| Fetal Blood | 1 | 1996 | 327 | 0.030 |
Why?
|
| Superoxides | 1 | 2014 | 199 | 0.030 |
Why?
|
| Arachidonic Acids | 1 | 2014 | 42 | 0.030 |
Why?
|
| Pre-B-Cell Leukemia Transcription Factor 1 | 1 | 2013 | 6 | 0.030 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2015 | 124 | 0.030 |
Why?
|
| Active Transport, Cell Nucleus | 2 | 2005 | 117 | 0.030 |
Why?
|
| Phosphorothioate Oligonucleotides | 1 | 2013 | 9 | 0.030 |
Why?
|
| Dyspnea | 1 | 2016 | 252 | 0.030 |
Why?
|
| Amino Acids, Branched-Chain | 1 | 2014 | 39 | 0.030 |
Why?
|
| Ribavirin | 1 | 2014 | 81 | 0.020 |
Why?
|
| Drug Administration Routes | 1 | 2013 | 42 | 0.020 |
Why?
|
| Serine | 1 | 2014 | 143 | 0.020 |
Why?
|
| MCF-7 Cells | 1 | 2014 | 133 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 1999 | 799 | 0.020 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1998 | 915 | 0.020 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2013 | 93 | 0.020 |
Why?
|
| Biocatalysis | 1 | 2013 | 68 | 0.020 |
Why?
|
| Immunotherapy | 1 | 2018 | 672 | 0.020 |
Why?
|
| Fatigue | 1 | 2016 | 367 | 0.020 |
Why?
|
| Caspases | 1 | 2014 | 233 | 0.020 |
Why?
|
| Fetus | 2 | 1995 | 805 | 0.020 |
Why?
|
| Transplant Recipients | 1 | 2015 | 183 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 2 | 2005 | 387 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2016 | 1386 | 0.020 |
Why?
|
| Child | 4 | 2020 | 22979 | 0.020 |
Why?
|
| Pandemics | 1 | 2021 | 1720 | 0.020 |
Why?
|
| HIV-1 | 1 | 1999 | 917 | 0.020 |
Why?
|
| Transcription Factor RelB | 1 | 2012 | 3 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2012 | 139 | 0.020 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2015 | 459 | 0.020 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2015 | 539 | 0.020 |
Why?
|
| Opportunistic Infections | 1 | 1992 | 47 | 0.020 |
Why?
|
| Time Factors | 4 | 2004 | 7173 | 0.020 |
Why?
|
| Cell Size | 1 | 2012 | 94 | 0.020 |
Why?
|
| Escherichia coli | 1 | 2016 | 836 | 0.020 |
Why?
|
| Proto-Oncogenes | 1 | 1991 | 28 | 0.020 |
Why?
|
| Gene Expression Regulation | 2 | 2014 | 2625 | 0.020 |
Why?
|
| Urban Population | 1 | 2015 | 502 | 0.020 |
Why?
|
| Farnesyltranstransferase | 1 | 2011 | 21 | 0.020 |
Why?
|
| Immunocompetence | 1 | 2011 | 46 | 0.020 |
Why?
|
| Benzenesulfonates | 1 | 2011 | 23 | 0.020 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 2458 | 0.020 |
Why?
|
| Graft Rejection | 1 | 2015 | 523 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2013 | 789 | 0.020 |
Why?
|
| Cell Count | 1 | 2012 | 321 | 0.020 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 1992 | 135 | 0.020 |
Why?
|
| Leukocyte Common Antigens | 1 | 2011 | 87 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2011 | 200 | 0.020 |
Why?
|
| Doxorubicin | 1 | 2013 | 411 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2001 | 1798 | 0.020 |
Why?
|
| Diphosphonates | 1 | 2011 | 68 | 0.020 |
Why?
|
| Bone Resorption | 1 | 2011 | 81 | 0.020 |
Why?
|
| beta Catenin | 1 | 2013 | 254 | 0.020 |
Why?
|
| Infant | 3 | 2015 | 10194 | 0.020 |
Why?
|
| Genetic Linkage | 1 | 1991 | 273 | 0.020 |
Why?
|
| Risk Factors | 2 | 2016 | 11017 | 0.020 |
Why?
|
| Bone Density Conservation Agents | 1 | 2011 | 82 | 0.020 |
Why?
|
| Adolescent | 3 | 2019 | 22825 | 0.020 |
Why?
|
| Receptors, Fibronectin | 1 | 1990 | 6 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2013 | 1281 | 0.020 |
Why?
|
| Blotting, Southern | 1 | 1990 | 85 | 0.020 |
Why?
|
| Virus Replication | 2 | 2004 | 521 | 0.020 |
Why?
|
| Nuclear Pore Complex Proteins | 1 | 2010 | 40 | 0.020 |
Why?
|
| Transplantation, Isogeneic | 1 | 1990 | 17 | 0.020 |
Why?
|
| Imidazoles | 1 | 2011 | 247 | 0.020 |
Why?
|
| Receptor, Notch1 | 1 | 2010 | 63 | 0.020 |
Why?
|
| Antigens, Surface | 1 | 1990 | 155 | 0.020 |
Why?
|
| Thioredoxins | 1 | 2009 | 30 | 0.020 |
Why?
|
| Galactosyltransferases | 1 | 1989 | 12 | 0.020 |
Why?
|
| Fibronectins | 1 | 1990 | 136 | 0.020 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2009 | 21 | 0.020 |
Why?
|
| Bacterial Proteins | 1 | 2016 | 976 | 0.020 |
Why?
|
| Radiation Tolerance | 1 | 2010 | 103 | 0.020 |
Why?
|
| Extracellular Space | 1 | 2009 | 117 | 0.020 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 849 | 0.020 |
Why?
|
| Neoplasm Staging | 1 | 2013 | 1492 | 0.020 |
Why?
|
| Antibody Affinity | 1 | 2009 | 60 | 0.020 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 2009 | 112 | 0.020 |
Why?
|
| CD40 Ligand | 1 | 2008 | 40 | 0.020 |
Why?
|
| Solubility | 1 | 2009 | 240 | 0.020 |
Why?
|
| Cell Adhesion | 1 | 1990 | 451 | 0.020 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2009 | 81 | 0.020 |
Why?
|
| Genes, abl | 1 | 2008 | 4 | 0.020 |
Why?
|
| Secondary Prevention | 1 | 2010 | 253 | 0.020 |
Why?
|
| Genes, p16 | 1 | 2008 | 13 | 0.020 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 1989 | 99 | 0.020 |
Why?
|
| Child, Preschool | 3 | 2015 | 12016 | 0.020 |
Why?
|
| MutL Protein Homolog 1 | 1 | 2008 | 11 | 0.020 |
Why?
|
| Interleukin-4 | 1 | 2008 | 207 | 0.020 |
Why?
|
| B-Cell Activating Factor | 1 | 2007 | 21 | 0.020 |
Why?
|
| Models, Chemical | 1 | 2009 | 251 | 0.020 |
Why?
|
| Models, Immunological | 1 | 2008 | 99 | 0.020 |
Why?
|
| Lymphoma | 1 | 2009 | 253 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 1989 | 512 | 0.020 |
Why?
|
| Crystallography, X-Ray | 1 | 2009 | 487 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2013 | 1912 | 0.020 |
Why?
|
| Granulocytes | 2 | 1999 | 83 | 0.020 |
Why?
|
| Glycoproteins | 1 | 1989 | 358 | 0.020 |
Why?
|
| Group V Phospholipases A2 | 1 | 2007 | 2 | 0.020 |
Why?
|
| Phospholipases A2 | 1 | 2007 | 79 | 0.020 |
Why?
|
| Algorithms | 1 | 2015 | 1868 | 0.020 |
Why?
|
| Pyridines | 1 | 2011 | 610 | 0.020 |
Why?
|
| Deoxycytidine | 1 | 2008 | 220 | 0.020 |
Why?
|
| Information Dissemination | 1 | 2009 | 227 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2009 | 322 | 0.020 |
Why?
|
| Nerve Tissue Proteins | 1 | 2010 | 597 | 0.020 |
Why?
|
| Serrate-Jagged Proteins | 1 | 2006 | 27 | 0.010 |
Why?
|
| Jagged-1 Protein | 1 | 2006 | 22 | 0.010 |
Why?
|
| Health Services Accessibility | 1 | 2015 | 1121 | 0.010 |
Why?
|
| Adenylyl Cyclases | 1 | 2006 | 60 | 0.010 |
Why?
|
| Antioxidants | 1 | 2009 | 550 | 0.010 |
Why?
|
| Water | 1 | 2009 | 452 | 0.010 |
Why?
|
| Lipoproteins | 1 | 2007 | 166 | 0.010 |
Why?
|
| Cyclic AMP-Dependent Protein Kinases | 1 | 2006 | 125 | 0.010 |
Why?
|
| Ornithine Decarboxylase | 1 | 2005 | 13 | 0.010 |
Why?
|
| Epigenesis, Genetic | 1 | 2010 | 708 | 0.010 |
Why?
|
| Killer Cells, Natural | 1 | 2008 | 481 | 0.010 |
Why?
|
| Hospitalization | 1 | 2015 | 2496 | 0.010 |
Why?
|
| Aging | 1 | 1995 | 1992 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 2015 | 1940 | 0.010 |
Why?
|
| Cytoplasm | 1 | 2005 | 255 | 0.010 |
Why?
|
| MAP Kinase Signaling System | 1 | 2006 | 308 | 0.010 |
Why?
|
| Ligands | 1 | 2006 | 675 | 0.010 |
Why?
|
| Genes, myc | 1 | 2003 | 51 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2016 | 8164 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 2003 | 273 | 0.010 |
Why?
|
| DNA, Neoplasm | 1 | 2003 | 163 | 0.010 |
Why?
|
| Promoter Regions, Genetic | 1 | 2008 | 1253 | 0.010 |
Why?
|
| Expressed Sequence Tags | 1 | 2002 | 43 | 0.010 |
Why?
|
| Lipopolysaccharide Receptors | 1 | 2002 | 88 | 0.010 |
Why?
|
| Genes, Reporter | 1 | 2002 | 278 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 2003 | 1049 | 0.010 |
Why?
|
| Pregnancy | 2 | 1997 | 7274 | 0.010 |
Why?
|
| Sequence Alignment | 1 | 2002 | 362 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2007 | 2017 | 0.010 |
Why?
|
| Luminescent Proteins | 1 | 2002 | 187 | 0.010 |
Why?
|
| Cell Nucleus | 1 | 2005 | 589 | 0.010 |
Why?
|
| Cell Culture Techniques | 1 | 2004 | 375 | 0.010 |
Why?
|
| Green Fluorescent Proteins | 1 | 2002 | 407 | 0.010 |
Why?
|
| DNA, Viral | 1 | 2002 | 357 | 0.010 |
Why?
|
| Tissue Donors | 1 | 2004 | 427 | 0.010 |
Why?
|
| CD24 Antigen | 1 | 1999 | 18 | 0.010 |
Why?
|
| Stem Cell Factor | 1 | 1999 | 16 | 0.010 |
Why?
|
| Leukapheresis | 1 | 1999 | 27 | 0.010 |
Why?
|
| United States Food and Drug Administration | 1 | 2000 | 208 | 0.010 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 1 | 1999 | 90 | 0.010 |
Why?
|
| Whole-Body Irradiation | 1 | 1999 | 74 | 0.010 |
Why?
|
| Leukemia Virus, Murine | 1 | 1999 | 17 | 0.010 |
Why?
|
| Tissue and Organ Harvesting | 1 | 1999 | 78 | 0.010 |
Why?
|
| Macaca mulatta | 1 | 1999 | 187 | 0.010 |
Why?
|
| Congresses as Topic | 1 | 2000 | 226 | 0.010 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 1224 | 0.010 |
Why?
|
| RNA, Viral | 1 | 2002 | 695 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2000 | 268 | 0.010 |
Why?
|
| Macrophage Colony-Stimulating Factor | 1 | 1998 | 20 | 0.010 |
Why?
|
| Histocytochemistry | 1 | 1998 | 79 | 0.010 |
Why?
|
| Alkaline Phosphatase | 1 | 1998 | 145 | 0.010 |
Why?
|
| Transgenes | 1 | 1998 | 190 | 0.010 |
Why?
|
| Transformation, Genetic | 1 | 1997 | 14 | 0.010 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1998 | 161 | 0.010 |
Why?
|
| Fibroblasts | 1 | 2002 | 1039 | 0.010 |
Why?
|
| Sodium-Phosphate Cotransporter Proteins | 1 | 1996 | 10 | 0.010 |
Why?
|
| 3T3 Cells | 1 | 1997 | 157 | 0.010 |
Why?
|
| HIV Infections | 1 | 1992 | 3235 | 0.010 |
Why?
|
| Dendritic Cells | 1 | 1998 | 510 | 0.010 |
Why?
|
| B-Lymphocytes | 1 | 1999 | 878 | 0.010 |
Why?
|
| Antibodies | 1 | 1994 | 398 | 0.010 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1992 | 43 | 0.010 |
Why?
|
| Pneumonia, Pneumocystis | 1 | 1992 | 34 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 1993 | 285 | 0.010 |
Why?
|
| Muridae | 1 | 1991 | 6 | 0.010 |
Why?
|
| Leukocyte Count | 1 | 1992 | 319 | 0.010 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1991 | 158 | 0.010 |
Why?
|
| Crosses, Genetic | 1 | 1991 | 123 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 1991 | 203 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 1999 | 2017 | 0.010 |
Why?
|
| Multigene Family | 1 | 1991 | 210 | 0.010 |
Why?
|
| Chromosome Mapping | 1 | 1991 | 512 | 0.000 |
Why?
|
| Cloning, Molecular | 1 | 1991 | 539 | 0.000 |
Why?
|
| Thymus Gland | 1 | 1991 | 313 | 0.000 |
Why?
|
| Bacterial Infections | 1 | 1992 | 247 | 0.000 |
Why?
|
| Receptors, Laminin | 1 | 1989 | 2 | 0.000 |
Why?
|
| Galactose | 1 | 1989 | 34 | 0.000 |
Why?
|
| Laminin | 1 | 1989 | 73 | 0.000 |
Why?
|
| Molecular Weight | 1 | 1989 | 313 | 0.000 |
Why?
|
| Immunoblotting | 1 | 1989 | 296 | 0.000 |
Why?
|
| Glycosylation | 1 | 1989 | 176 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 1992 | 2080 | 0.000 |
Why?
|
| Incidence | 1 | 1992 | 2954 | 0.000 |
Why?
|
| United States | 1 | 2000 | 16313 | 0.000 |
Why?
|